Possibilities of phytotherapy оf prostate diseases

1. Vuichoud C., Loughlin K.R. Benign prostatic hyperplasia: epidemiology, economics and evaluation // Can J Urol. 2015. Vol. 22. Suppl. 1. P. 1–6. 2. Amerson D. Urolift for BPH: changing the game in BPH care, presentation at AACU State Advocacy Conference. Chicago. IL. Sept 18‒19 2015. 3. Avins A.L., Bent S., Staccone S. et al. A detailed safety assessment of a saw palmetto extract // Complement Ther Med. 2008. Vol. 16(3). P. 147‒154. doi: 10.1016/j.ctim.2007.10.005 4. Pinggera G.M., Frauscher F. Do we really need herbal medicine in LUTS/BPH treatment in the 21st century? // Expert Opin Drug Saf. 2016. Vol. 15(12). P. 1573‒1575. 5. Nickel J.C., Roehrborn C.G., Castro-Santamaria R. et al. Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention // J Urol. 2016. Vol. 196(5). P. 1493‒1498. doi: 10.1016/j.juro.2016.06.090 6. Kramer G., Mitteregger D., Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? // Eur Urol. 2007. Vol. 51(5). P. 1202‒1216. 7. Gandaglia G., Zaffuto E., Fossati N. et al. The role of prostatic inflammation in the development and progression of benign and malignant diseases // Curr Opin Urol. 2017. Vol. 27(2). P. 99‒106. doi: 10.1097/MOU.0000000000000369 8. Vignozzi L., Gacci M., Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome // Nat Rev Urol. 2016. Vol. 13(2). P. 108‒119. doi: 10.1038/nrurol.2015.301 9. Осадчий А.В., Кульчавеня Е.В., Рейхруд Т.А. и др. Социально-демографическая характеристика больных туберкулезом легких и внелегочных локализаций // Туберкулез и болезни легких. 2015. №2. С. 46–49 [Osadchij A.V., Kulchavenya E.V., Rejhrud T.A. i dr. Social’no-demograficheskaya harakteristika bol’nyh tuberkulezom legkih i vnelegochnyh lokalizacij // Tuberkulez i bolezni legkih. 2015. №2. S. 46‒49 (in Russian)]. 10. Кульчавеня Е.В., Чередниченко А.Г., Неймарк А.И., Шевченко С.Ю. Частота встречаемости уропатогенов и динамика их чувствительности // Урология. 2015. №2. С. 13‒16 [Kulchavenya E.V., Cherednichenko A.G., Nejmark A.I., SHevchenko S.Yu. Chastota vstrechaemosti uropatogenov i dinamika ih chuvstvitel’nosti // Urologiya. 2015. №2. S. 13‒16 (in Russian)]. 11. Miotła P., Dobruch J., Lipiński M. et al. Diagnostic and therapeutic recommendations for patients with nocturia. // Cent European J Urol. 2017. Vol. 70(4). P. 388‒393. doi: 10.5173/ceju.2017.1563 12. Cai T., Tamanini I., Kulchavenya E. et al. The role of nutraceuticals and phytotherapy in the management of urinary tract infections: what we need to know? // Archivio Italiano di Urologia Andrologia. 2017. Vol. 89(1). P. 1‒6. 13. Ng K.K., Ng F.C. The use of antimuscarinics, phosphodiesterase type V inhibitors and phytotherapy for lower urinary tract symptoms in men. // Asian J Urol. 2017. Vol. 4(3). P. 191‒194. doi: 10.1016/j.ajur.2017.05.002 14. Perry R., Milligan G., Anderson P. et al. Real-world use of Permixon® in benign prostatic hyperplasia-determining appropriate monotherapy and combination treatment // Adv Ther. 2012. Vol. 29(6). P. 538–550. doi: 10.1007/s12325-012-0024-x 15. Novara G., Giannarini G., Alcaraz A. et al. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials // Eur Urol Focus. 2016. Vol. 2(5). P. 553‒561. doi: 10.1016/j.euf.2016.04.002 16. Ooi S.L., Pak S.C. Serenoa repens for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Current Evidence and Its Clinical Implications in Naturopathic Medicine // J Altern Complement Med. 2017. Vol. 23(8). P. 599‒606. doi: 10.1089/acm.2016.0302. Epub 2017 Apr 24. 17. Kageyama S., Beppu M., Ohnogi H. et al. Clinical Effects of Formulated Food of Peucedanum japonicum Extract and Saw Palmetto Extract in Male Patients with Lower Urinary Tract Symptoms // Low Urin Tract Symptoms. 2017. Vol. 4. doi: 10.1111/luts.12155 18. Ju X.B., Gu X.J., Zhang Z.Y. et al. Efficacy and safety of Saw Palmetto Extract Capsules in the treatment of benign prostatic hyperplasia // Zhonghua Nan Ke Xue. 2015. Vol. 21(12). P. 1098‒1101. 19. Kane C.J., Raheem O.A., Bent S., Avins A.L. What do I tell patients about saw palmetto for benign prostatic hyperplasia? // Urol Clin North Am. 2011. Vol. 38(3). P. 261‒277. doi: 10.1016/j.ucl.2011.04.005. Review. 20. Görne R.C., Wegener T., Kelber O. et al. Randomized double-blind controlled clinical trials with herbal preparations of Serenoa repens fruits in treatment of lower urinary tract symptoms: An overview // Wien Med Wochenschr. 2017. Vol. 167(7–8). P. 177‒182. doi: 10.1007/s10354-016-0526-2 21. Белостоцкая Л.И., Никитченко Ю.В., Гомон О.Н. и др. Влияние биологически активных веществ животного и растительного происхождения на прооксидантно-антиоксидантный баланс при экспериментальной гиперплазии предстательной железы у крыс // Экспериментальная и клиническая фармакология. 2006. Т. 69. №4. С. 66‒68 [Belostockaya L.I., Nikitchenko Yu.V., Gomon O.N. i dr. Vliyanie biologicheski aktivnyh veshchestv zhivotnogo i rastitel’nogo proiskhozhdeniya na prooksidantno-antioksidantnyj balans pri ehksperimental’noj giperplazii predstatel’noj zhelezy u krys // EHksperimental’naya i klinicheskaya farmakologiya. 2006. T. 69. №4. S. 66‒68 (in Russian)]. 22. Bernichtein S., Pigat N., Camparo P. et al. Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia // Prostate. 2015. Vol. 75(7). P. 706‒722. doi: 10.1002/pros.22953 23. Silvestri I., Cattarino S., Aglianò A. et al. Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma // J Inflamm (Lond). 2013. Vol. 10. P. 11. doi: 10.1186/1476-9255-10-11 24. Latil A., Pétrissans M.T., Rouquet J. et al. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia // Prostate. 2015. Vol. 75(16). P. 1857–1867. doi: 10.1002/pros.23059. Epub 2015 Aug 26. 25. Сивков А.В., Ощепков В.Н., Медведев А.М. Болезни предстательной железы. Первые результаты применения липидостеролового экстракта Serenoa repens у больных хроническим абактериальным простатитом // Consilium Medicum. 2005. Т. 7. №7. С. 582‒586 [Sivkov A.V., Oshchepkov V.N., Medvedev A.M. Bolezni predstatel’noj zhelezy. Pervye rezul’taty primeneniya lipidosterolovogo ehkstrakta Serenoa repens u bol’nyh hronicheskim abakterial’nym prostatitom // Consilium Medicum. 2005. T. 7. №7. S. 582‒586 (in Russian)]. 26. Giammusso B., Di Mauro R., Bernardini R. The efficacy of an association of palmitoylethanolamide and alpha-lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial // Arch Ital Urol Androl. 2017. Vol. 89(1). P. 17‒21. doi: 10.4081/aiua.2017.1.17 27. Лопаткин Н.А., Аполихин О.И., Сивков А.В. Результаты мультицентрового исследования экстракта Serenoa repens (Пермиксон) у больных хроническим абактериальным простатитом // Урология. 2007. №7. С. 3‒7 [Lopatkin N.A., Apolihin O.I., Sivkov A.V. Rezul’taty mul’ticentrovogo issledovaniya ehkstrakta Serenoa repens (Permikson) u bol’nyh hronicheskim abakterial’nym prostatitom // Urologiya. 2007. №7. S. 3‒7 (in Russian)]. 28. Anceschi R., Bisi M., Ghidini N. et al. Serenoa repens (Permixon®) reduces intra- and postoperative complications of surgical treatments of benign prostatic hyperplasia // Minerva Urol Nefrol. 2010. Vol. 62(3). P. 219–223. 29. Пытель Ю.А., Лопаткин Н.А., Гориловский Л.М. и др. Результаты долгосрочного применения пермиксона у больных с симптомами нарушения функции нижних мочевых путей // Урология. 2004. №2. С. 3‒7 [Pytel’ Yu.A., Lopatkin N.A., Gorilovskij L.M. i dr. Rezul’taty dolgosrochnogo primeneniya permiksona u bol’nyh s simptomami narusheniya funkcii nizhnih mochevyh putej // Urologiya. 2004. №3. S. 3‒7 (in Russian)]. 30. Ткачук В.Н., Гребенкин А.Г. Оценка эффективности и безопасности длительного лечения больных доброкачественной гиперплазией предстательной железы препаратами растительного происхождения // Нефрология. 2005. Т. 9. №1. С. 79‒82 [Tkachuk V.N., Grebenkin A.G. Ocenka ehffektivnosti i bezopasnosti dlitel’nogo lecheniya bol’nyh dobrokachestvennoj giperplaziej predstatel’noj zhelezy preparatami rastitel’nogo proiskhozhdeniya // Nefrologiya. 2005. T. 9. №1. S. 79–82 (in Russian)]. 31. Аляев Ю.Г., Винаров А.З., Локшин К.Л., Спивак Л.Г. Экстракты Serenoa repens в лечении аденомы предстательной железы и хронического абактериального простатита: результаты краткосрочных (3-месячных) курсов лечения // Урология. 2007. № 2. С. 80‒82 [Alyaev Yu.G., Vinarov A.Z., Lokshin K.L., Spivak L.G. EHkstrakty Serenoa repens v lechenii adenomy predstatel’noj zhelezy i hronicheskogo abakterial’nogo prostatita: rezul’taty kratkosrochnyh (3-mesyachnyh) kursov lecheniya // Urologiya.2007. № 2. S. 80–82 (in Russian)]. 32. Saidi S., Stavridis S., Stankov O. et al. Effects of Serenoa repens Alcohol Extract on Benign Prostate Hyperplasia // Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017. Vol. 38(2). P. 123‒129. doi: 10.1515/prilozi-2017-0030 33. Chiavaroli A., Recinella L., Ferrante C. et al. Crocus sativus, Serenoa repens and Pinus massoniana extracts modulate inflammatory response in isolated rat prostate challenged with LPS // J Biol Regul Homeost Agents. 2017. Vol. 31(3). P. 531–541. 34. Boeri L., Capogrosso P., Ventimiglia E. et al. Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone // Sci Rep. 2017. Vol. 7(1). P. 15179. doi: 10.1038/s41598-017-15435-0) 35. Traish A.M. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men. // Adv Exp Med Biol. 2017. Vol. 1043. P. 473‒526. doi: 10.1007/978-3-319-70178-3_22 36. Gupta A.K., Carviel J., Gupta M.A, Shear N.H. Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System. // J Eur Acad Dermatol Venereol. 2017. doi: 10.1111/jdv.14728 37. Jun J.E.J., Kinkade A., Tung A.C.H., Tejani A.M. 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. // Can J Hosp Pharm. 2017. Vol. 70(2). P. 113‒119. 38. Di Silverio, Bosman C., Salvatori M. et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) // Eur Urol. 2005. Vol. 47(1). P. 72‒79. 39. Falaharkar S., Mokhtari G., Pourreza F. et al. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study // Urol. 2008. Vol. 72(4). P. 813‒816. doi: 10.1016/j.urology.2008.04.069 40. Kahokehr S., Vather R., Nixon A., Hill A.G. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials // BJUI. 2013. Vol. 111(2). P. 304‒311. doi: 10.1111/j.1464-410X.2012.11559.x 41. Грегори Р. Терапия доброкачественной гиперплазии предстательной железы: в фокусе – воспаление (доклад на XVII конгрессе Российского общества урологов, Москва, 8–10 ноября 2017) // РМЖ. 2017. №27. С. 2003–2010. https://www.rmj.ru/articles/urologiya/Terapiya_dobrokachestvennoy_giperplazii_predstatelynoy_ghelezy_v_fokuse__vospaleniedoklad_professora_Gregori_Roberta_v_ramkah_XVII_kongressa_Rossiyskogo_obschestva_urologov/#ixzz56EYu4m6D. [Gregori R. Terapiya dobrokachestvennoj giperplazii predstatel’noj zhelezy: v fokuse – vospalenie (doklad na XVII kongressa Rossijskogo obshchestva urologov, Moskva, 8–10 noyabrya 2017) // RMZh. 2017. №27. S. 2003–2010. https://www.rmj.ru/articles/urologiya/Terapiya_dobrokachestvennoy_giperplazii_predstatelynoy_ghelezy_v_fokuse__vospaleniedoklad_professora_Gregori_Roberta_v_ramkah_XVII_kongressa_Rossiyskogo_obschestva_urologov/#ixzz56EYu4m6D (in Russian)]. 42. Vela Navarrete. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay // Eur Urol. 2003. Vol. 44(5). P. 549‒555. 43. Pauber-Braquet M., Mencia Huerta J.M., Cousse H., Braquet P. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils // Prostaglandins Leukot Essent Fatty Acids. 1997. Vol. 57(3). P. 299‒304. 44. Latil A., Libon C., Templier M. et al. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro // BJU Int. 2012. Vol. 110(6). P. 301‒307. doi: 10.1111/j.1464-410X.2012.11144.x